High-Terlin Terazosin Hydrochloride Tablets

This product is a yellow flat round tablet with a logo and a triangular scratch on one side.

This product is suitable for the treatment of mild or moderate hypertension when taken orally. It can be used in combination with thiazide diuretics or other antihypertensive drugs. It can also be used alone when other drugs are not suitable or ineffective. This product mainly reduces diastolic blood pressure. This product is also suitable for the symptomatic treatment of urinary retention caused by benign prostatic hyperplasia (BPH).

The initial dose for hypertension is 1 mg taken before bedtime, and should not be exceeded to minimize the occurrence of hypotension events with the first dose. After one week, the daily single dose can be doubled to achieve the desired effect. The commonly used maintenance dose is 2-10 mg once a day. No increase in efficacy has been observed with doses exceeding 20 mg, and doses above 40 mg have not been studied. The dosage for benign prostatic hyperplasia (BPH) is adjusted according to the patient's response. The initial dose is 1 mg taken before bedtime, and should not be exceeded to minimize the occurrence of hypotension events with the first dose. After one or two weeks, the daily dose can be doubled to achieve the desired effect. The commonly used maintenance dose is 5-10 mg once a day. Symptoms are significantly improved after two weeks of administration. So far, there is not enough data to show that doses exceeding 10 mg once a day will cause further symptom relief. Treatment should be started with the initial dose and the efficacy summary should be conducted after four weeks. Temporary adverse reactions may occur with each dose adjustment. If adverse reactions persist, a dose reduction should be considered.

The most common adverse reactions are: weakness, palpitations, nausea, peripheral edema, dizziness, drowsiness, congestion, rhinitis and blurred vision/amblyopia. In addition, the following adverse reactions have also been reported: back pain, headache, tachycardia, postural hypotension, syncope, edema, weight gain, pain in the extremities, decreased libido, depression, nervousness, paresthesia, dyspnea, sinusitis, impotence. Other adverse reactions reported in clinical trials and adverse reactions that are not clearly related to the use of this product in market feedback reports: chest pain, facial edema, fever, abdominal pain, neck pain, shoulder pain, vasodilation, arrhythmia, constipation, diarrhea, dry mouth, dyspepsia, flatulence, vomiting, gout, arthralgia, arthritis, joint disorders, myalgia, anxiety, insomnia, bronchitis, epistaxis, flu symptoms, pharyngitis, rhinitis, cold symptoms, itching, (skin) rash, cough, sweating, abnormal vision, conjunctivitis, tinnitus, frequent urination, urinary tract infection and early urinary incontinence in postmenopausal women. At least two cases of allergic reactions have been reported with the use of this product. Thrombocytopenia and priapism have been reported with the use of this product, and atrial fibrillation has also been reported: but a causal relationship has not yet been established. Laboratory tests: In clinical controlled trials, a small but statistically significant decrease in hematocrit, hemoglobin, white blood cells, total protein and albumin was found. These laboratory results indicate the possibility of plasma dilution. Continuous use of this product for more than 24 months has no significant effect on prostate-specific antigen (PSA) levels.

It is contraindicated in patients with known sensitivity to alpha-adrenergic receptor antagonists.

2mg